Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis

Hepatology Research

Volumn 37, Issue 7, 2007, Pages 503-509

  Koga, Hiroyuki ^a   Ide, Tatsuya ^a   Oho, Kazuhiko ^a   Kuwahara, Reiichiro ^a   Hino, Teruko ^a   Ogata, Kei ^a   Hisamochi, Akiko ^a   Tanaka, Kazuo ^a   Kumashiro, Ryukichi ^a   Toyonaga, Atsushi ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cirrhosis; Esophageal varices; Lamivudine

Indexed keywords

HYALURONIC ACID; LAMIVUDINE; NEOMINOPHAGEN C; URSODEOXYCHOLIC ACID; VIRUS DNA;

ADULT; AGED; ARTICLE; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; VIRUS STRAIN;

EID: 34249894424     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00087.x     Document Type: Article

References (22)

1. Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-12.
2. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
3. Manolakopoulos S, Karatapanis S, Elefsiniotis J et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63.
4. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-16.
5. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000; 6: 715-20.
6. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-66.
7. Hanada S, Kumashiro R, Kaji R, Harada M, Sata M. Additional benefit of lamivudine treatment as a preventive therapy for hepatic encephalopathy in patients with decompensated liver cirrhosis associated with hepatitis B. Int J Mol Med 2002; 10: 647-8.
8. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
9. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
10. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 125663.
11. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7.
12. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha-interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-8.
13. Dienstag JL, Goldine RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
14. Japanese Research Society for Portal Hypertension. The general rules for recording endoscopic findings on esophageal varices. Jpn J Surg 1980; 10: 84-7.
15. Colombo M, de Franchis R, Tommasini M, Sangiovanni A, Dioguardi N. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology 1989; 9: 433-8.
16. Hayes PC, Davis JM, Lewis JA, Bouchier LA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336: 153-6.
17. Bernard B, Lebrec D, Mathurin P, Opolon P. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta analysis. Hepatology 1997; 25: 63-70.
18. Ueno T, Tanikawa K. Clinical application of serum hyaluronan for liver diseases and its significance. In: Kennedy JF, Phillips GO, Williams PA, Hascall VC, eds. Hyaluronan Vol. 2. Biomedical, Medical and Clinical Aspects. London: Woodhead, 2002; 445-52.
19. Tamaki S, Ueno T, Torimura T, Sata M, Tanikawa K. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in rats with liver cirrhosis. Gastroenterology 1996; 111: 1049-57.
20. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
21. Peters MG, Hann HWH, Martin P et al. Adefovir dipivoxil alone or combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
22. Kuwahara R, Kumashiro R, Inoue H et al. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains. Digest Dis Sci 2004; 49: 300-3.